Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine (VNP40101M) and Cytarabine in Relapsed AML

Jan. 8, 2008 -- Vion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) had lifted the clinical hold on the Phase III trial (Vion Study CLI-037) of its lead anti-cancer agent, Cloretazine (VNP40101M), in combination with cytarabine in relapsed acute myelogenous leukemia (AML).